超高频甲钴胺治疗早期肌萎缩侧索硬化症的疗效与安全性:一项随机临床试验
这项多中心、安慰剂对照、双盲、随机3期临床试验在日本25个神经内科中心开展,纳入病程1年内的肌萎缩侧索硬化症患者,经过12周观察后随机分组,肌内注射甲钴胺50mg或安慰剂每周两次共16周。主要终点为修订版肌萎缩侧索硬化功能评分量表总分从基线至第16周的变化,甲钴胺组较安慰剂组少下降1.97分(-2.66 vs -4.63;95%CI 0.44-3.50;P=0.01),两组不良事件发生率相似。
要点
- 超高频甲钴胺(50mg肌内注射每周两次)治疗16周可减缓早期肌萎缩侧索硬化症患者的功能下降。
- 第16周时甲钴胺组修订版肌萎缩侧索硬化功能评分量表总分较基线下降2.66分,安慰剂组下降4.63分,组间差异1.97分(95%CI 0.44-3.50;P=0.01)。
- 两组不良事件发生率相似,16周治疗期间安全性良好。
核心结论
- 超高频甲钴胺可减缓早期且进展速度中等肌萎缩侧索硬化症患者的功能下降,且在16周治疗期间安全。
研究设计与样本
- 多中心、安慰剂对照、双盲、随机3期临床试验,包含12周观察期和16周随机治疗期,于2017年10月17日至2019年9月30日在日本25个神经内科中心开展。
- 初步纳入病程1年内依据更新版Awaji标准诊断的肌萎缩侧索硬化症患者,经12周观察后符合以下条件者进入随机分组:修订版肌萎缩侧索硬化功能评分量表总分下降1分或2分、用力肺活量百分比大于60%、无非侵入性呼吸支持或气管切开史、可行走。
- 目标样本量为甲钴胺组和安慰剂组各64例,通过电子网络应答系统随机分配。
- 共130例患者被随机分配至甲钴胺组或安慰剂组(每组65例),平均(标准差)年龄61.0(11.7)岁,男性74例(56.9%)。
- 全分析集纳入129例患者,126例完成双盲阶段,其中124例进入开放标签扩展期。
主要发现
- 第16周时甲钴胺组修订版肌萎缩侧索硬化功能评分量表总分最小二乘均值变化为-2.66分,安慰剂组为-4.63分,组间差异为1.97分(95%CI 0.44-3.50;P=0.01)。
- 两组不良事件发生率相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effectiveness of currently approved drugs for amyotrophic lateral sclerosis (ALS) is restricted; there is a need to develop further treatments. Initial studies have shown ultrahigh-dose methylcobalamin to be a promising agent. OBJECTIVE: To validate the efficacy and safety of ultrahigh-dose methylcobalamin for patients with ALS enrolled within 1 year of onset. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, placebo-controlled, double-blind, randomized phase 3 clinical trial with a 12-week observation and 16-week randomized period, conducted from October 17, 2017, to September 30, 2019. Patients were recruited from 25 neurology centers in Japan; those with ALS diagnosed within 1 year of onset by the updated Awaji criteria were initially enrolled. Of those, patients fulfilling the following criteria after 12-week observation were eligible for randomization: 1- or 2-point decrease in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score, a percent forced vital capacity greater than 60%, no history of noninvasive respiratory support and tracheostomy, and being ambulatory. The target participant number was 64 in both the methylcobalamin and placebo groups. Patients were randomly assigned through an electronic web-response system to methylcobalamin or placebo. INTERVENTIONS: Intramuscular injection of methylcobalamin (50-mg dose) or placebo twice weekly for 16 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was change in ALSFRS-R total score from baseline to week 16 in the full analysis set. RESULTS: A total of 130 patients (mean [SD] age, 61.0 [11.7] years; 74 men [56.9%]) were randomly assigned to methylcobalamin or placebo (65 each). A total of 129 patients were eligible for the full analysis set, and 126 completed the double-blind stage. Of these, 124 patients proceeded to the open-label extended period. The least square means difference in ALSFRS-R total score at week 16 of the randomized period was 1.97 points greater with methylcobalamin than placebo (-2.66 vs -4.63; 95% CI, 0.44-3.50; P = .01). The incidence of adverse events was similar between the 2 groups. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that ultrahigh-dose methylcobalamin was efficacious in slowing functional decline in patients with early-stage ALS and with moderate progression rate and was safe to use during the 16-week treatment period. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03548311.
引用
- Oki R, Izumi Y, Fujita K, et al. Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 35532908. doi:10.1001/jamaneurol.2022.0901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。